Evidence map›Paper›PMID 36199843›Full record

ArticleMateria socio-medica2022

Association of Inherited Genotype and Severity of Clinical Presentation in Subjects with Verified Pas III Disorder.

Vanja Karlovic Beslic, Azra Burekovic, Zahida Drace, Zelija Velija-Asimi, Amela Dizdarevic-Bostandzic

Open access · greenAbstract read
In one paragraph

Article in Materia socio-medica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Vanja Karlovic BeslicClinical for Nuclaer Medicine and Endocrinology, Clinical Center Univeristy of Sarajevo, Bosnia and Herzegovina.
Azra BurekovicClinical for Nuclaer Medicine and Endocrinology, Clinical Center Univeristy of Sarajevo, Bosnia and Herzegovina.
Zahida DraceSSST University in Sarajevo, Bosnia and Herzegovina.
Zelija Velija-AsimiSSST University in Sarajevo, Bosnia and Herzegovina.
Amela Dizdarevic-BostandzicClinical for Nuclaer Medicine and Endocrinology, Clinical Center Univeristy of Sarajevo, Bosnia and Herzegovina.
University of Sarajevo · BA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Polyglandular autoimmune syndrome type III (PAS III) is combination two most common autoimmune disease: Diabetes mellytus type 1 (DM1) and autoimmune thyroid disease (AITD). Objectives: The aims of the study were a) to define conection between polymorphism of CTLA-4 gene, rs 231775 with PAS III; b) to establish the conection of inherited genotype with severity of clinical features; and c) to estimate the rate of risk for severe clinical presentation among subgroups in study population. Methods: This research included 50 subjects with diagnosed PAS III syndrome, wich are on treatment in clinic for Nuclear medicine and andocrinology KCUS. As methods of research has used: hystory of disesase AND clinical examination. As material is used blood sample. From blood sample DNA was isolated withn Qiamp- DNA-mini kit, with accopanied protocol. Results: In our study, 50 patients with polyglandular autoimmune syndrome type III (PAS III) were examined, and in the study population had 26 female subjects and 24 male subjects. The average age of the participants was 31.64 years, and in the subgroups: group GWT (G-wild type) the average age was 30.20 years, group GM (G-mutated) 32.40 years and group GH (G-heterozygote) 30 , 60 years. Using the Chi-square test, the association between the polymorphism rs231775 and PAS-III was demonstrated, x2 (2.100) = 18.258, where p < 0.0001. Using the Chi-square test, the association between the rs231775 polymorphism and the severity of the clinical picture, x2 (2.50) = 8.531, where p< 0.0140 was proved. The CTLA-4 rs231775 genotypes were also assessed for disease severity. Conclusion: This study suggests that CTLA-4 expression plays a key role in balancing the immune system as well as the response against one's own tissues, and thus in the regulation of autoimmune diseases.

Indexed as

hypothyroidism levothyroxine dosingpluriglandular disorder PAS IIIseverity of clinical picturetype 1 diabetes mellitus

Identifiers

PMID36199843
PMCPMC9478524
OpenAlexW4285223960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.